Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine
Science Advances · 2025
DOI: 10.1126/sciadv.adq2887 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Science Advances, 2025. Verfasst von Constantino López-Macías und 38 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Soc…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Low- and middle-income countries face substantial challenges in immunizing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including high costs, limited access, and insufficient local manufacturing. To address these issues, we developed and locally manufactured the AVX/COVID-12 vaccine using a cost-effective Newcastle disease virus LaSota platform to express a stabilized SARS-CoV-2 spike protein (HexaPro-S). We evaluated the AVX/COVID-12 vaccine in a phase 2/3 parallel-group, double-blind, active-controlled, noninferiority trial with 4056 volunteers, demonstrating its safety, good tolerability, and ability to induce neutralizing antibodies against ancestral SARS-CoV-2 and the Omicron BA.2 and BA.5 variants. It also stimulated interferon-γ–producing CD8 + T cells and met the World Health Organization’s noninferiority criteria compared to AZ/ChAdOx-1-S. No vaccinated participants experienced severe disease, hospitalization, or death. These findings support the use of AVX/COVID-12 as a booster to help achieve and maintain population immunity while addressing global inequities in vaccine distribution, and it has been approved for adult booster use in Mexico.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México (CDMX), México.
- Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) "Ismael Cosío Villegas," CDMX, México.
- iLS Clinical Research S.C., CDMX, México.
- Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, CDMX, México.
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), CDMX, México.
- CAIMED Investigación en Salud S.A. de C.V., CDMX, México.
ORCID-Profile: Constantino López-Macías, Martha Torres, Brenda Armenta-Copca, Niels H Wacher, Arturo Galindo-Fraga, Laura Castro-Castrezana, Andrea Alicia Colli-Domínguez, Edgar Cervantes-Trujano, Fernando Lozano-Patiño, Juan José Rivera-Alcocer, Abraham Simón-Campos, Efrén Alberto Sánchez-Campos, Rafael Aguirre-Rivero, Alejandro José Muñiz-Carvajal, Luis Del Carpio-Orantes, Francisco Márquez-Díaz, Alejandro Torres-Flores, Luis Ramírez-Martínez, Georgina Paz-De la Rosa, Oscar Rojas-Martínez, Alejandro Suárez-Martínez, Gustavo Peralta-Sánchez, Claudia Carranza, Esmeralda Juárez, Horacio Zamudio-Meza, Laura E Carreto-Binaghi, Mercedes Viettri, Damaris Romero-Rodríguez, Andrea Palencia, David Sarfati-Mizrahi, Weina Sun, Héctor Elías Chagoya-Cortés, Peter Palese, Florian Krammer, Adolfo García-Sastre, Bernardo Lozano-Dubernard
Zitieren
APA
López-Macías, C., Torres, M., Armenta-Copca, B., Wacher, N. H., Galindo-Fraga, A., Castro-Castrezana, L., Colli-Domínguez, A. A., Cervantes-Trujano, E., Rucker-Joerg, I. E., Lozano-Patiño, F., Rivera-Alcocer, J. J., Simón-Campos, A., Sánchez-Campos, E. A., Aguirre-Rivero, R., Muñiz-Carvajal, A. J., Del Carpio-Orantes, L., Márquez-Díaz, F., Rivera-Hernández, T., Torres-Flores, A., …, & Lozano-Dubernard, B. (2025). Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine. Science Advances. https://doi.org/10.1126/sciadv.adq2887
Vancouver
López-Macías C, Torres M, Armenta-Copca B, Wacher NH, Galindo-Fraga A, Castro-Castrezana L, et al. Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine. Science Advances. 2025. doi:10.1126/sciadv.adq2887
BibTeX
@article{LpezMacas2025,
author = {López-Macías, Constantino and Torres, Martha and Armenta-Copca, Brenda and Wacher, Niels H and Galindo-Fraga, Arturo and Castro-Castrezana, Laura and Colli-Domínguez, Andrea Alicia and Cervantes-Trujano, Edgar and Rucker-Joerg, Isabel Erika and Lozano-Patiño, Fernando and Rivera-Alcocer, Juan José and Simón-Campos, Abraham and Sánchez-Campos, Efrén Alberto and Aguirre-Rivero, Rafael and Muñiz-Carvajal, Alejandro José and Del Carpio-Orantes, Luis and Márquez-Díaz, Francisco and Rivera-Hernández, Tania and Torres-Flores, Alejandro and Ramírez-Martínez, Luis and la Rosa, Georgina Paz-De and Rojas-Martínez, Oscar and Suárez-Martínez, Alejandro and Peralta-Sánchez, Gustavo and Carranza, Claudia and Juárez, Esmeralda and Zamudio-Meza, Horacio and Carreto-Binaghi, Laura E and Viettri, Mercedes and Romero-Rodríguez, Damaris and Palencia, Andrea and Sarfati-Mizrahi, David and Sun, Weina and Chagoya-Cortés, Héctor Elías and Castro-Peralta, Felipa and Palese, Peter and Krammer, Florian and García-Sastre, Adolfo and Lozano-Dubernard, Bernardo},
title = {Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adq2887}
}
EUVIMED